Evidence map›Paper›PMID 36717880›Full record

ArticleBMC health services research2023

COVID-19's impact on care practice for alpha-1-antitrypsin deficiency patients.

Myriam Calle Rubio, José Luis López-Campos, Marc Miravitlles, Francisco Javier Michel de la Rosa, José María Hernández Pérez, Carmen Montero Martínez, José Bruno Montoro Ronsano, Francisco Casas Maldonado, Juan Luis Rodríguez Hermosa, Eva María Tabernero Huguet and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Myriam Calle RubioPulmonology Department, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), San Carlos Clinical Hospital, Madrid, Spain.
José Luis López-CamposMedical-Surgical Unit for Respiratory Diseases, Biomedicine Institute of Sevilla (IBiS), Virgen del Rocío University Hospital, Seville, Spain.
Marc MiravitllesPulmonology Department, Research Institute of Vall d'Hebron (VHIR), Vall d'Hebron University Hospital, Barcelona, Spain.
Francisco Javier Michel de la RosaPulmonology Department, Donostia University Hospital, San Sebastián, Spain.
José María Hernández PérezNetwork of Centers for Biomedical Research On Respiratory Diseases (CIBERES), Carlos III Health Institute, Madrid, Spain.
Carmen Montero MartínezPulmonology Department, A Coruña University Hospital, A Coruña, Spain.
José Bruno Montoro RonsanoDepartment of Pharmacy, Vall d'Hebron University Hospital, Barcelona, Spain.
Francisco Casas MaldonadoPulmonology Department, San Cecilio Clinical University Hospital, Granada, Spain.
Juan Luis Rodríguez HermosaPulmonology Department, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), San Carlos Clinical Hospital, Madrid, Spain.
Eva María Tabernero HuguetPulmonology Department, Cruces University Hospital, Barakaldo, Spain.
José Manuel Martínez SesmeroDepartment of Pharmacy, San Carlos Clinical Hospital, Madrid, Spain.
Carlos Martínez RiveraNetwork of Centers for Biomedical Research On Respiratory Diseases (CIBERES), Carlos III Health Institute, Madrid, Spain.
Francisco Javier Callejas GonzálezPulmonology Department, Albacete University Hospital Complex, Albacete, Spain.
María Torres DuránPulmonology Department, Health Research Institute of Galicia Sur (IISGS), Álvaro Cunqueiro Hospital, Estrada Clara Campoamor, 342. 36312, Vigo, Spain. maria.luisa.torres.duran@sergas.es.
Instituto de Salud Carlos III · ESUniversidad Complutense de Madrid · ESBiogipuzkoa Health Research Institute · ESHospital Clínico San Carlos · ESHospital de Cruces · ESInstituto de Biomedicina de Sevilla · ESUniversidad de Granada · ESUniversidade da Coruña · ESUniversity Hospital Complex Of Vigo · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with alpha-1 antitrypsin deficiency (AATD), commonly categorized as a rare disease, have been affected by the changes in healthcare management brought about by COVID-19. This study's aim was to identify the changes that have taken place in AATD patient care as a result of the COVID-19 pandemic in Spain and to propose experts' recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation.

methodsA qualitative descriptive case study with a holistic single-case design was conducted, using focus groups with experts in AATD clinical management, including 15 health professionals with ties to the Spanish health system (12 pneumologists and 2 hospital pharmacists from 11 different hospitals in Spain) and 1 patient representative.

resultsCOVID-19 has had a major impact on numerous aspects of AATD clinical patient management in Spain, including diagnostic, treatment, and follow-up phases. The experts concluded that there is a need to strengthen coordination between Primary Care and Hospital Care and improve the coordination processes across all the organizations and actors involved in the healthcare system. Regarding telemedicine and telecare, experts have concluded that it is necessary to promote this methodology and to develop protocols and training programs. Experts have recommended developing personalized and precision medicine, and patient participation in decision-making, promoting self-care and patient autonomy to optimize their healthcare and improve their quality of life. The possibility of monitoring and treating AATD patients from home has also been proposed by experts. Another result of the study was the recommendation of the need to ensure that plasma donations are made on a regular basis by a sufficient number of healthy individuals.

conclusionThe study advances knowledge by highlighting the challenges faced by health professionals and changes in AATD patient management in the context of the COVID-19 pandemic. It also proposes experts' recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. This work could serve as a reference study for physicians on their daily clinical practice with AATD patients and may also provide guidance on the changes to be put in place for the post-pandemic situation.

Indexed as

alpha 1-Antitrypsin DeficiencyCOVID-19Pulmonary Disease, Chronic ObstructiveDelivery of Health CareHumansPandemicsQuality of LifeAATDAlpha-1-antitrypsin deficiencyCOVID-19DiagnosticFollow-upHealthcare systemPatient managementRare diseaseRecommendationsTreatment

Identifiers

PMID36717880
PMCPMC9885054
OpenAlexW4318465485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.